Find Clinical Trial

A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

IndicationLymphoma, Solid tumors
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device

AG-270

Active Substance CodeAG-270
Protocol CodeAG270-C-001
EudraCT Code2017-004384-13
NCT CodeNCT03435250


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility